Influence of preoperative Lynch syndrome diagnosis on surgery in patients with colorectal cancer.
Abstract
94 Background: Lynch Syndrome (LS) can guide surgery for colorectal cancer (CRC), particularly for MLH1/MSH2 carriers, who may benefit from extended procedures: total colectomy (TC) or total proctocolectomy (TP). We investigated timing of germline genetic testing (GGT) and surgical approach in patients (pts) with LS and CRC. Methods: Integrated GGT (Labcorp, formerly Invitae Corp.) and insurance claims (Komodo Healthcare Map) data for adult pts with non-metastatic colon (CC) or rectal (RC) cancer and CRC surgery from 2015-23, ≥ 6 months of claims pre-CRC diagnosis, and GGT for EPCAM, MLH1, MSH2, MSH6, and PMS2 . Χ 2 and t tests and multivariable logistic regression compared GGT results and surgical approach. Results: Of 1616 CRC pts (1553 CC, 63 RC), 15% were LS positive (15% CC, 11% RC). Compared to pts with negative GGT, pts with LS were more likely male, Black, younger at diagnosis and GGT, to have family history of GI/any cancer and to have GGT pre-CRC surgery. Of 129 LS pts with CC and MLH1/MSH2/EPCAM, 41 (32%) had GGT pre-surgery and 20/41 (49%) had TC/TP (Table). 5/6 (83%) of the corresponding RC pts had GGT pre-surgery and 3/5 (60%) had TP. 88 CC MLH1 / MSH2 / EPCAM pts had GGT post-surgery and 17/88 (19%) had TC/TP. 1 MLH1 / MSH2 / EPCAM RC patient had GGT post-surgery and 0 had TP. More CC pts had TC/TP than RC pts (p<0.001). Compared to pts with negative GGT, pts with LS and CRC were more likely to have TC/TP (21% vs. 6%, p<0.001), particularly with GGT pre-surgery (43% vs. 13%, p<0.001). RC LS pts with GGT pre-surgery had shorter mean months from GGT to surgery than pts with negative GGT (6 vs 14, p=0.026). CC pts with MLH1 or MSH2/EPCAM and GGT pre-surgery had higher odds of undergoing TC/TP (odds ratio (OR): 6, confidence interval (CI): 3-10; OR: 7, CI: 4-14; OR: 4, CI: 2-6) than pts with negative or post-surgery GGT. Conclusions: GGT performed pre-surgery for a new diagnosis of CRC was more likely to result in extended procedures, especially in MLH1/MSH2/EPCAM carriers. More data in RC is needed to better understand the influence of GGT on surgical approach. CC surgery type and timing in relation to GGT. Pts w/ CC surgery GGT pre-surgery (N=295) GGT post-surgery (N=1258) Total Partial Colectomy (N=245)N (% total) TC/TP (N=50) N (% total) P-value: partial vs TC/TP^ Total Partial Colectomy (N=1203)N (% total) TC/TP (N=55)N (% total) P-value: partial vs TC/TP^ MLH1 (N=75) 24 (32) 13 (54) 11 (46) 0.001 51 (68) 42 (82) 9 (18) <0.001 MSH2/ EPCAM (N=54) 17 (32) 8 (47) 9 (53) 0.006 37 (69) 29 (78) 8 (22) <0.001 MSH6 (N=49) 13 (27) 11 (85) 2 (15) 1 36 (74) 35 (97) 1 (3) 1 PMS2 (N=51) 6 (12) 3 (50) 3 (50) 0.252 45 (88) 43 (96) 2 (4) 1 LS positive (N=229) 60 (26) 35 (58) 25 (42) <0.001 169 (74) 149 (88) 20 (12) <0.001 LS VUS (N=61) 6 (10) 6 (100) 0 (0) 1 55 (90) 55 (100) 0 (0) 0.526 LS Negative (N=1263) 229 (18) 204 (89) 25 (11) <0.001 1034 (82) 995 (96) 39 (4) 0.006 Note: Excludes pts with RC due to small N. ^Adjusted for multiple testing.
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (6)
Mohammad Ali Abbass
Memorial Sloan Kettering Cancer Center, New York, NY
Sarah M. Nielsen Young
Invitae, San Fransisco, CA
Emily M. Russell
Labcorp (formerly Invitae Corp.), San Francisco, CA
Ed Esplin
Labcorp Genetics, San Francisco, CA
Daniel Pineda-Alvarez
Previous Affiliation Labcorp (formerly Invitae Corp.), San Francisco, CA
Brandie Heald
Exact Sciences, Madison, WI